secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265711
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian closes $289M equity, $300M royalty financing; BLA submitted for veligrotug in TED
--------------------------------------------------------------------------------

- Cash position ~$887.9M as of Oct 31, 2025, up from $490.9M at Sep 30, after equity, royalty, and debt financings.
- BLA for veligrotug (IV) in thyroid eye disease submitted to FDA Oct 2025 with Priority Review request; mid-2026 launch targeted if approved.
- Subcutaneous VRDN-003 topline data accelerated: REVEAL-1 in Q1 2026, REVEAL-2 in Q2 2026; both trials exceeded enrollment targets (132 and 204 patients).
- R&D expenses $86.3M in Q3 2025 (up 25% YoY) driven by Ph3 programs; G&A $24.3M (up 69% YoY) from launch prep.
- VRDN-006 showed IgG reduction proof-of-concept in Ph1; VRDN-008 IND on track for year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/0001193125-25-265711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525265711/d33707d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer